Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.60
TEAR's Cash to Debt is ranked lower than
60% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. TEAR: 1.60 )
Ranked among companies with meaningful Cash to Debt only.
TEAR' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: 1.6

Equity to Asset 0.46
TEAR's Equity to Asset is ranked lower than
71% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. TEAR: 0.46 )
Ranked among companies with meaningful Equity to Asset only.
TEAR' s 10-Year Equity to Asset Range
Min: -1.1   Max: 0.96
Current: 0.46

-1.1
0.96
Interest Coverage No Debt
TEAR's Interest Coverage is ranked higher than
91% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3194.09 vs. TEAR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
TEAR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: -16.06
M-Score: -4.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -129.83
TEAR's Operating margin (%) is ranked lower than
78% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. TEAR: -129.83 )
Ranked among companies with meaningful Operating margin (%) only.
TEAR' s 10-Year Operating margin (%) Range
Min: -48893.1   Max: -121.37
Current: -129.83

-48893.1
-121.37
Net-margin (%) -125.90
TEAR's Net-margin (%) is ranked lower than
77% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.29 vs. TEAR: -125.90 )
Ranked among companies with meaningful Net-margin (%) only.
TEAR' s 10-Year Net-margin (%) Range
Min: -75902.17   Max: -120.31
Current: -125.9

-75902.17
-120.31
ROE (%) -89.98
TEAR's ROE (%) is ranked lower than
84% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.73 vs. TEAR: -89.98 )
Ranked among companies with meaningful ROE (%) only.
TEAR' s 10-Year ROE (%) Range
Min: -214.14   Max: -15.27
Current: -89.98

-214.14
-15.27
ROA (%) -68.80
TEAR's ROA (%) is ranked lower than
83% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. TEAR: -68.80 )
Ranked among companies with meaningful ROA (%) only.
TEAR' s 10-Year ROA (%) Range
Min: -715.24   Max: -14.38
Current: -68.8

-715.24
-14.38
ROC (Joel Greenblatt) (%) -553.35
TEAR's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.57 vs. TEAR: -553.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TEAR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8269.06   Max: -630.38
Current: -553.35

-8269.06
-630.38
Revenue Growth (3Y)(%) 69.10
TEAR's Revenue Growth (3Y)(%) is ranked higher than
96% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. TEAR: 69.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TEAR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 69.1
Current: 69.1

0
69.1
EBITDA Growth (3Y)(%) 18.60
TEAR's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. TEAR: 18.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TEAR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -77.8   Max: 97.5
Current: 18.6

-77.8
97.5
EPS Growth (3Y)(%) 12.40
TEAR's EPS Growth (3Y)(%) is ranked higher than
72% of the 98 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. TEAR: 12.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TEAR' s 10-Year EPS Growth (3Y)(%) Range
Min: -78.6   Max: 71.6
Current: 12.4

-78.6
71.6
» TEAR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

TEAR Guru Trades in Q2 2014

Chuck Royce 100,000 sh (-90.45%)
» More
Q3 2014

TEAR Guru Trades in Q3 2014

Chuck Royce 100,000 sh (unchged)
» More
Q4 2014

TEAR Guru Trades in Q4 2014

Chuck Royce 100,000 sh (unchged)
» More
Q1 2015

TEAR Guru Trades in Q1 2015

Chuck Royce 113,000 sh (+13.00%)
» More
» Details

Insider Trades

Latest Guru Trades with TEAR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.60
TEAR's P/B is ranked lower than
65% of the 210 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. TEAR: 4.60 )
Ranked among companies with meaningful P/B only.
TEAR' s 10-Year P/B Range
Min: 0.18   Max: 63.48
Current: 4.6

0.18
63.48
P/S 3.85
TEAR's P/S is ranked lower than
71% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.37 vs. TEAR: 3.85 )
Ranked among companies with meaningful P/S only.
TEAR' s 10-Year P/S Range
Min: 2.91   Max: 500
Current: 3.85

2.91
500
Current Ratio 5.46
TEAR's Current Ratio is ranked higher than
77% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. TEAR: 5.46 )
Ranked among companies with meaningful Current Ratio only.
TEAR' s 10-Year Current Ratio Range
Min: 0.19   Max: 20.62
Current: 5.46

0.19
20.62
Quick Ratio 4.88
TEAR's Quick Ratio is ranked higher than
76% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.35 vs. TEAR: 4.88 )
Ranked among companies with meaningful Quick Ratio only.
TEAR' s 10-Year Quick Ratio Range
Min: 0.14   Max: 19.15
Current: 4.88

0.14
19.15
Days Inventory 89.93
TEAR's Days Inventory is ranked lower than
59% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 75.12 vs. TEAR: 89.93 )
Ranked among companies with meaningful Days Inventory only.
TEAR' s 10-Year Days Inventory Range
Min: 61.57   Max: 383.57
Current: 89.93

61.57
383.57
Days Sales Outstanding 40.49
TEAR's Days Sales Outstanding is ranked higher than
81% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. TEAR: 40.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEAR' s 10-Year Days Sales Outstanding Range
Min: 13.1   Max: 1487.77
Current: 40.49

13.1
1487.77

Valuation & Return

vs
industry
vs
history
Price/Net Cash 26.60
TEAR's Price/Net Cash is ranked higher than
60% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.70 vs. TEAR: 26.60 )
Ranked among companies with meaningful Price/Net Cash only.
TEAR' s 10-Year Price/Net Cash Range
Min: 4.52   Max: 22.78
Current: 26.6

4.52
22.78
Price/Net Current Asset Value 12.60
TEAR's Price/Net Current Asset Value is ranked higher than
73% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.50 vs. TEAR: 12.60 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TEAR' s 10-Year Price/Net Current Asset Value Range
Min: 3.62   Max: 531
Current: 12.6

3.62
531
Price/Tangible Book 5.70
TEAR's Price/Tangible Book is ranked higher than
65% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.60 vs. TEAR: 5.70 )
Ranked among companies with meaningful Price/Tangible Book only.
TEAR' s 10-Year Price/Tangible Book Range
Min: 2.93   Max: 179.35
Current: 5.7

2.93
179.35
Price/Median PS Value 0.10
TEAR's Price/Median PS Value is ranked higher than
100% of the 202 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. TEAR: 0.10 )
Ranked among companies with meaningful Price/Median PS Value only.
TEAR' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 11.68
Current: 0.1

0.1
11.68
Earnings Yield (Greenblatt) -38.00
TEAR's Earnings Yield (Greenblatt) is ranked lower than
90% of the 210 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.10 vs. TEAR: -38.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
TEAR' s 10-Year Earnings Yield (Greenblatt) Range
Min: -65.1   Max: 0
Current: -38

-65.1
0

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:TLB.Canada, OCV1.Germany,
TearLab Corp was incorporated as OccuLogix, Inc. in Delaware in 2002. The Company is an in-vitro diagnostic company based in San Diego, California. The commercialized a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company's first product measures tear film osmolarity for the diagnosis of Dry Eye Disease, or DED. The Company's wholly-owned subsidiary, TearLab Research, Inc. develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites (glucose), genes and proteins) at the point-of-care. Commercializing that tear testing platform is the focus of the Company's business. The Company's first product, the TearLab Osmolarity System, enables the rapid measurement of tear osmolarity in the doctor's office. Osmolarity is a quantitative and specific biomarker that has been shown to assist in the diagnosis and disease management of DED. The innovation of the TearLab Osmolarity System is its ability to precisely and rapidly measure osmolarity in nanoliter volumes of tear samples, using an efficient and novel tear collection system at the point of care. The TearLab Osmolarity System consists of the following three components: the TearLab disposable, which is a single-use microfluidic microchip; the TearLab Pen, which is a hand-held device that interfaces with the TearLab disposable; and the TearLab Reader, which is a small desktop unit that allows for the docking of the TearLab Pen and provides a quantitative reading for the operator. The Company relies on two suppliers based in the United States for the manufacture of the Readers and Pens which are key components of the TearLab Osmolarity System. The Company also relies on a single supplier, MiniFAB (Aust) Pty Ltd. located in Australia, for the manufacture of the test cards which is also a key component of the TearLab Osmolarity System.
» More Articles for TEAR

Headlines

Articles On GuruFocus.com
comment on TEAR Mar 06 2013 

More From Other Websites
TearLab to Participate in the 12th Annual Craig-Hallum Institutional Investor Conference May 20 2015
TearLab to Participate in the 12th Annual Craig-Hallum Institutional Investor Conference May 20 2015
TEARLAB CORP Financials May 16 2015
TEARLAB CORP Files SEC form 8-K/A, Changes in Registrant's Certifying Accountant, Financial... May 14 2015
TEARLAB CORP Files SEC form 8-K/A, Financial Statements and Exhibits May 12 2015
TEARLAB CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 11 2015
10-Q for TearLab Corp. May 10 2015
TearLab Corporation Reports Q1-15 Financial Results May 07 2015
TearLab Corporation Reports Q1-15 Financial Results May 07 2015
Q1 2015 Tearlab Corp Earnings Release - After Market Close May 07 2015
10-K for TearLab Corp. May 05 2015
TEARLAB CORP Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements... May 01 2015
TearLab Corporation to Release Q1 2015 Financial Results on May 7, 2015 Apr 23 2015
TEARLAB CORP Files SEC form 10-K, Annual Report Mar 13 2015
TearLab Corporation Reports 2014 Financial Results Mar 12 2015
TearLab reports 4Q loss Mar 12 2015
TearLab reports 4Q loss Mar 12 2015
TEARLAB CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 12 2015
TearLab Corporation Reports 2014 Financial Results Mar 12 2015
TEARLAB CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Mar 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK